Clinical Cancer Research Grants Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blaveri, E.
Right arrow Articles by Waldman, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blaveri, E.
Right arrow Articles by Waldman, F. M.
Clinical Cancer Research Vol. 11, 7012-7022, October 1, 2005
© 2005 American Association for Cancer Research


Cancer Therapy: Preclinical

Bladder Cancer Stage and Outcome by Array-Based Comparative Genomic Hybridization

Ekaterini Blaveri1, Jeremy L. Brewer1, Ritu Roydasgupta2, Jane Fridlyand2, Sandy DeVries1, Theresa Koppie3, Sunanda Pejavar1, Kshama Mehta1, Peter Carroll3, Jeff P. Simko4 and Frederic M. Waldman1,2,3

Authors' Affiliations: Departments of 1 Laboratory Medicine, 2 Cancer Center, 3 Urology, and 4 Pathology, University of California San Francisco, San Francisco, California

Requests for reprints: Frederic Waldman, Department of Laboratory Medicine, University of California San Francisco Comprehensive Cancer Center, San Francisco, CA 94143-0808. Phone: 415-476-3821; Fax: 415-476-8218; E-mail: waldman{at}cc.ucsf.edu.

Purpose: Bladder carcinogenesis is believed to follow alternative pathways of disease progression driven by an accumulation of genetic alterations. The purpose of this study was to evaluate associations between measures of genomic instability and bladder cancer clinical phenotype.

Experimental Design: Genome-wide copy number profiles were obtained for 98 bladder tumors of diverse stages (29 pTa, 14 pT1, 55 pT2-4) and grades (21 low-grade and 8 high-grade superficial tumors) by array-based comparative genomic hybridization (CGH). Each array contained 2,464 bacterial artificial chromosome and P1 clones, providing an average resolution of 1.5 Mb across the genome. A total of 54 muscle-invasive cases had follow-up information available. Overall outcome analysis was done for patients with muscle-invasive tumors having "good" (alive >2 years) versus "bad" (dead in <2 years) prognosis.

Results: Array CGH analysis showed significant increases in copy number alterations and genomic instability with increasing stage and with outcome. The fraction of genome altered (FGA) was significantly different between tumors of different stages (pTa versus pT1, P = 0.0003; pTa versus pT2-4, P = 0.02; and pT1 versus pT2-4, P = 0.03). Individual clones that differed significantly between different tumor stages were identified after adjustment for multiple comparisons (false discovery rate < 0.05). For muscle-invasive tumors, the FGA was associated with patient outcome (bad versus good prognosis patients, P = 0.002) and was identified as the only independent predictor of overall outcome based on a multivariate Cox proportional hazards method. Unsupervised hierarchical clustering separated "good" and "bad" prognosis muscle-invasive tumors into clusters that showed significant association with FGA and survival (Kaplan-Meier, P = 0.019). Supervised tumor classification (prediction analysis for microarrays) had a 71% classification success rate based on 102 unique clones.

Conclusions: Array-based CGH identified quantitative and qualitative differences in DNA copy number alterations at high resolution according to tumor stage and grade. Fraction genome altered was associated with worse outcome in muscle-invasive tumors, independent of other clinicopathologic parameters. Measures of genomic instability add independent power to outcome prediction of bladder tumors.




This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
C. J. Rosser, L. Liu, Y. Sun, P. Villicana, M. McCullers, S. Porvasnik, P. R. Young, A. S. Parker, and S. Goodison
Bladder Cancer-Associated Gene Expression Signatures Identified by Profiling of Exfoliated Urothelia
Cancer Epidemiol. Biomarkers Prev., February 1, 2009; 18(2): 444 - 453.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. J.H. Coenen, M. Ploeg, M. M.V.A.P. Schijvenaars, E. B. Cornel, H. F.M. Karthaus, H. Scheffer, J. A. Witjes, B. Franke, and L. A.L.M. Kiemeney
Allelic Imbalance Analysis Using a Single-Nucleotide Polymorphism Microarray for the Detection of Bladder Cancer Recurrence
Clin. Cancer Res., December 15, 2008; 14(24): 8198 - 8204.
[Abstract] [Full Text] [PDF]


Home page
BioinformaticsHome page
F. Rapaport, E. Barillot, and J.-P. Vert
Classification of arrayCGH data using fused SVM
Bioinformatics, July 1, 2008; 24(13): i375 - i382.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Veerakumarasivam, H. E. Scott, S.-F. Chin, A. Warren, M. J. Wallard, D. Grimmer, K. Ichimura, C. Caldas, V. P. Collins, D. E. Neal, et al.
High-Resolution Array-Based Comparative Genomic Hybridization of Bladder Cancers Identifies Mouse Double Minute 4 (MDM4) as an Amplification Target Exclusive of MDM2 and TP53
Clin. Cancer Res., May 1, 2008; 14(9): 2527 - 2534.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
B. I. Ferreira, J. F. Garcia, J. Suela, M. Mollejo, F. I. Camacho, A. Carro, S. Montes, M. A. Piris, and J. C. Cigudosa
Comparative genome profiling across subtypes of low-grade B-cell lymphoma identifies type-specific and common aberrations that target genes with a role in B-cell neoplasia
Haematologica, May 1, 2008; 93(5): 670 - 679.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
C. J. Marsit, E. A. Houseman, A. R. Schned, M. R. Karagas, and K. T. Kelsey
Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer
Carcinogenesis, August 1, 2007; 28(8): 1745 - 1751.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. A. Knowles
Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?
Carcinogenesis, March 1, 2006; 27(3): 361 - 373.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.